Voyager Therapeutics
Voyager Therapeutics' revenue fell 49.5% to $40 million in fiscal 2025. Its operating margin was −326.6%, down from −104.1% a year earlier. Free cash flow was −$135 million. The diluted share count rose 1.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2020 to 2023, earnings per share grew 44.7% a year and net income 53.3% a year, as new shares raised the share count by 20% and diluted each share's earnings. Voyager Therapeutics then lost money in fiscal 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 132 | 119 | 231 | 332 | 202 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 2.7x | 1.7x | 5.0x | 5.6x | 7.6x |
| Quick ratio | 2.7x | 1.7x | 5.0x | 5.6x | 7.6x |
Cash flow
Projections
Project Voyager Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Voyager Therapeutics shares on the open market, and 4 insiders sold $297,957, $220,709 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | Alfred SandrockPresident and CEO, Director | Sold plan | 11,511 | $3.87 | $44,548 | Form 4 |
| Feb 24, 2026 | Alfred SandrockPresident and CEO, Director | Sold plan | 14,197 | $3.79 | $53,807 | Form 4 |
| Feb 24, 2026 | Robin SwartzCOO & Cbo | Sold plan | 6,458 | $3.77 | $24,347 | Form 4 |
| Feb 24, 2026 | Nathan D. JorgensenChief Financial Officer | Sold plan | 4,668 | $3.77 | $17,598 | Form 4 |
| Feb 24, 2026 | Todd Alfred CarterChief Scientific Officer | Sold plan | 4,174 | $3.76 | $15,694 | Form 4 |
| Feb 18, 2026 | Alfred SandrockPresident and CEO, Director | Sold plan | 11,732 | $3.41 | $40,006 | Form 4 |
| Feb 18, 2026 | Robin SwartzCOO & Cbo | Sold plan | 3,882 | $3.44 | $13,354 | Form 4 |
| Feb 18, 2026 | Todd Alfred CarterChief Scientific Officer | Sold plan | 3,301 | $3.44 | $11,355 | Form 4 |
| Feb 10, 2026 | Alfred SandrockPresident and CEO, Director | Sold | 12,192 | $3.78 | $46,086 | Form 4 |
| Feb 10, 2026 | Robin SwartzCOO & Cbo | Sold | 4,569 | $3.85 | $17,591 | Form 4 |
| Feb 10, 2026 | Todd Alfred CarterChief Scientific Officer | Sold | 3,525 | $3.85 | $13,571 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 541.0% | −91.5% | −384.1% |
| Altman Z'' | 6.83 | 3.03 | −1.03 |
| Accruals ratio | 21.3% | −13.3% | 4.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Voyager Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Voyager Therapeutics | FY25 | −49.5% | −326.6% | −334.5% | — | — | — | |
| Editas Medicine | FY25 | 25.4% | −394.9% | −409.3% | — | — | 2 | Compare |
| Kymera Therapeutics | FY25 | −16.7% | −891.1% | −597.6% | — | — | — | Compare |
| Coherus Oncology | FY25 | 59.8% | −429.5% | — | — | — | — | Compare |
| Wave Life Sciences | FY25 | −60.5% | −504.1% | −440.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 14 | 10 | 8 | 104 | 171 | 37 | 41 | 250 | 80 | 40 |
| Revenue growth | −18.0% | −28.7% | −24.8% | 1,270.1% | 63.9% | −78.1% | 9.3% | 511.2% | −68.0% | −49.5% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 42 | 62 | 65 | 120 | 109 | 74 | 61 | 92 | 127 | 135 |
| Operating income | −41 | −72 | −91 | −52 | 27 | −74 | −51 | 122 | −83 | −132 |
| Net income | −40 | −71 | −88 | −44 | 37 | −71 | −46 | 132 | −65 | −120 |
| Diluted EPS (US$) | −1.59 | −2.64 | −2.75 | −1.21 | 0.98 | −1.89 | −1.21 | 2.97 | −1.13 | −2.04 |
| Diluted shares (millions) | 25 | 27 | 32 | 36 | 37 | 38 | 38 | 45 | 58 | 59 |
| Cash flow | ||||||||||
| Cash from operations | −42 | −61 | −16 | 49 | −97 | −54 | −12 | 78 | −15 | −132 |
| Capital expenditure | 5 | 4 | 4 | 8 | 12 | 2 | 2 | 3 | 4 | 3 |
| Free cash flow | −48 | −65 | −20 | 41 | −109 | −55 | −15 | 75 | −19 | −135 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 9 | 16 | 16 | 15 | 11 | 9 | 11 | 15 | 15 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 174 | 169 | 156 | 282 | 181 | 132 | 119 | 231 | 332 | 202 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 190 | 184 | 177 | 355 | 262 | 194 | 159 | 351 | 393 | 252 |
| Total liabilities | 54 | 50 | 131 | 255 | 107 | 99 | 100 | 115 | 93 | 56 |
| Shareholders' equity | 136 | 134 | 46 | 100 | 154 | 95 | 59 | 236 | 300 | 196 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −290.4% | −709.1% | −1,195.6% | −49.5% | 16.0% | −196.8% | −124.3% | 48.8% | −104.1% | −326.6% |
| Net margin | −282.6% | −697.6% | −1,158.8% | −41.8% | 21.5% | −190.3% | −113.5% | 52.9% | −81.2% | −296.5% |
| Free cash flow margin | −334.1% | −644.6% | −265.0% | 39.2% | −63.6% | −147.4% | −36.7% | 29.9% | −23.5% | −334.5% |
| Rule of 40 (growth + FCF margin) | −352.1% | −673.4% | −289.9% | 1,309.4% | 0.3% | −225.5% | −27.3% | 541.0% | −91.5% | −384.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −26.4% | −52.4% | −97.8% | −59.7% | 28.9% | −57.1% | −60.2% | 89.6% | −24.2% | −48.3% |
| Return on assets | −19.2% | −37.8% | −48.8% | −16.4% | 11.9% | −31.3% | −26.3% | 51.8% | −17.5% | −37.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |